The new statistical report titled as Oncology Drugs Market has recently published by Absolute
Markets Insights. This study comprises mix data containing the recent trends,
technological platforms, tools, and certain methodologies. It gives an overview
of the market dynamics such as the changing needs of the clients in different
regions. This research report offers a comprehensive analysis of different
parameters of businesses like profit margin, shares and pricing structures. It
has been compiled by using qualitative and quantitative analysis techniques.
The valuable insights of businesses have been examined by using primary and
secondary research methodologies in a particular manner.
A section containing the data about
different factors influencing the progress of the Oncology Drugs market. This
research report offers a bird’s eye view on the historical as well as current
trends operating in the global Oncology Drugs market. Different market segment
and its sub-segment have been elaborated to understand the market clearly.
Leading key players have been profiled to get detailed data about company
profiles, contact details, and revenue of the companies.
Top Key Players includes: F.
Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli Lilly and
Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca, Merck & Co.,
Inc.,CELGENE CORPORATION and Polaris Pharmaceuticals amongst others
For More Information Click@ https://www.absolutemarketsinsights.com/reports/Oncology-Drugs-Market-2019-2027-273
In terms of revenue, global oncology drugs
market was valued at US$ 119 billion in 2020. The introduction and approval of
anti-PD-1 agents’ nivolumab and pembrolizumab for NSCLC has bought a new era
for the cancer industry. The number of patients receiving single-agent
chemotherapy decreased considerably in the recent past and the patients who
received EGFR-TKI based therapy also reduced substantially
Single drug therapies coupled with monoclonal
antibodies against programmed death-1 (PD-1) and programmed death ligand-1
(PD-L1) have shown little efficacy in patients suffering from metastatic breast
cancer. The same is low number of tumour-infiltrating lymphocytes, found in
most of the breast cancers. As a result, the development of combinations of
molecularly targeted therapies and immunotherapy have proven to be a great
success.
The China and United States hold the leading
positions in the cancer cell therapy pipeline. The number for the same are 439
and 305 agents respectively. Majority of the drugs developed in the United
States are at pre-clinical stage, whereas the drugs that are being developed in
China are at clinical stages
In August, 2019, the U.S. FDA granted approval
to Rozlytrek. This drug is for adoslescents and adult who are suffering from
genetic cancer defects. This drug got approval for treating diseases like NTRK
(neurotrophic tyrosine receptor kinase) gene fusion. The drug has a unique
ability to shrink tumors and has been evaluated in four clinical trials,
studying the adults who are suffering from NTRK fusion-positive tumors.
Oncology Drugs Market
Segmentation:
By Indication
- Breast
Cancer
- Prostate
Cancer
- Basal
Cell Cancer
- Skin
Cancer (Non-Melanoma)
- Colorectal
cancer
- Lung
Cancer
- Renal
Cancer
- Bladder
Cancer
- Lymphoma
- Others
By Treatment
- Drug
Therapies
- Antimetabolites
- Antitumor
Antibiotics
- Asparagine-Specific
Enzymes
- Bisphosphonates
& Biosimilars
- DNA-Damaging
Agents (Antineoplastics) and Alkylating Agents
- Inhibitors
- DNA-Repair
Enzyme Inhibitors
- Histone
Deacetylase Inhibitors
- Janus-Associated
Kinase (JAK) Inhibitors
- Phosphoinositide
3-kinase inhibitors (PI3K inhibitors)
- Proteasome
Inhibitors
- Tyrosine
Kinase Inhibitors
- PD-1
and PD-L1 inhibitors
- Others
- Monoclonal
Antibodies
- Others
- Surgery
- Open
Surgery
- Minimally
Invasive Surgery
- Radiation
Therapy
- Chemotherapy
- Immunotherapy
- Chimeric
antigen receptor (CAR) T-cell therapy
- Cytokine
Treatment
- Donor
lymphocyte infusion
- Monoclonal
Antibody Treatment
- Others
- Targeted
Therapy
- Hormone
Therapy
- Stem
Cell Transplant
- Autologous
stem cell transplantation
- Allogeneic
stem cell transplantation
- Reduced-Intensity
Allogeneic Stem Cell Transplantation
- Graft-Versus-Host
Disease
- Precision
Medicine
- Others
By Region
- North
America
- Europe
- Asia
Pacific
- Middle
East and Africa
- Latin
America
Why Buy this Report?
·
Extensive analysis on latest trends and growth opportunities
in different regions across the globe
·
Comprehensive assessment on recent technological
advancements and forecast of the upcoming period
·
A comparative analysis of leading players and
emerging players in the Oncology Drugs market
·
Authentic information on new product launches,
organic and inorganic strategies, and more
·
Valuable insights on the impact of regulatory
framework on the global Oncology Drugs market
Contact Us:
Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-7400-24-24-24, US +1-510-420-1213
Website: www.absolutemarketsinsights.com
No comments:
Post a Comment